JP2005529152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529152A5 JP2005529152A5 JP2004505078A JP2004505078A JP2005529152A5 JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5 JP 2004505078 A JP2004505078 A JP 2004505078A JP 2004505078 A JP2004505078 A JP 2004505078A JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- antibody
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000004965 antibodies Human genes 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 8
- 102100012093 CDAN1 Human genes 0.000 claims 2
- 101700043553 CDAN1 Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 101000018804 IFNG Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 102000028267 human IFNG protein Human genes 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003472 neutralizing Effects 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15074202A | 2002-05-17 | 2002-05-17 | |
| US38331002P | 2002-05-22 | 2002-05-22 | |
| PCT/US2003/015874 WO2003097082A2 (en) | 2002-05-17 | 2003-05-16 | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005529152A JP2005529152A (ja) | 2005-09-29 |
| JP2005529152A5 true JP2005529152A5 (lt) | 2006-07-06 |
Family
ID=29552737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505078A Pending JP2005529152A (ja) | 2002-05-17 | 2003-05-16 | 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1506002A4 (lt) |
| JP (1) | JP2005529152A (lt) |
| AU (1) | AU2003231802A1 (lt) |
| CA (1) | CA2486147A1 (lt) |
| WO (1) | WO2003097082A2 (lt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014467A1 (en) | 1992-12-29 | 1994-07-07 | Genentech, Inc. | Treatment of inflammatory bowel disease with ifn-gamma inhibitors |
| ATE541859T1 (de) * | 2005-01-27 | 2012-02-15 | Novimmune Sa | Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung |
| US20090186047A1 (en) * | 2006-04-25 | 2009-07-23 | Intercell Ag | HCV Vaccinations |
| KR20100126515A (ko) * | 2008-03-18 | 2010-12-01 | 아보트 러보러터리즈 | 건선의 치료방법 |
| CN104159919A (zh) | 2011-11-23 | 2014-11-19 | 安姆根有限公司 | 使用抗干扰素γ抗体的治疗方法 |
| MA41271A (fr) * | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| EA037532B1 (ru) | 2015-05-07 | 2021-04-08 | Новиммун Са | Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994014467A1 (en) * | 1992-12-29 | 1994-07-07 | Genentech, Inc. | Treatment of inflammatory bowel disease with ifn-gamma inhibitors |
| US6350860B1 (en) * | 1997-08-18 | 2002-02-26 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| US20050019323A1 (en) * | 2002-05-22 | 2005-01-27 | Protein Design Labs, Inc. | Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies |
-
2003
- 2003-05-16 WO PCT/US2003/015874 patent/WO2003097082A2/en active Application Filing
- 2003-05-16 EP EP03753102A patent/EP1506002A4/en not_active Withdrawn
- 2003-05-16 CA CA002486147A patent/CA2486147A1/en not_active Abandoned
- 2003-05-16 JP JP2004505078A patent/JP2005529152A/ja active Pending
- 2003-05-16 AU AU2003231802A patent/AU2003231802A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019196370A5 (lt) | ||
| JP2015187125A5 (lt) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2016074740A5 (lt) | ||
| JP2016514132A5 (lt) | ||
| JP2014114288A5 (lt) | ||
| JP2013533858A5 (lt) | ||
| RU2019125748A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2020002172A5 (lt) | ||
| JP2016516016A5 (lt) | ||
| JP2007515469A5 (lt) | ||
| JP2018532715A5 (lt) | ||
| JP2017537105A5 (lt) | ||
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2018531938A5 (lt) | ||
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| JP2015172060A5 (lt) | ||
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| IL299376A (en) | Fixed dose combination of pertuzumab plus transtuzumab | |
| JP2019521156A5 (lt) | ||
| JP2005506345A5 (lt) | ||
| AU647463B2 (en) | A method and a pharmaceutical preparation for treating pain | |
| JP2006508039A5 (lt) | ||
| JP2021004249A5 (lt) | ||
| JP2005529152A5 (lt) |